Cat No.
CEI-0547
Description
Cell-permeable. An ethyl ester derivative of the JMJD3 selective histone demethylase inhibitor GSK-J1 (IC50> 50 μM in vitro. When administered to human primary macrophages, GSK-J4 can reduce lipopolysaccharide (LPS)-induced proinflammatory cytokine production, most notably including that of TNFα (IC50 = 9 μM).
Product_Overview
Histone demethylase JMJD3/UTX inhibitor
Targets
KDM6B
Chemical Name
?Ethyl 3-?((6-?(4,?5-?dihydro-?1H-?benzo[d]azepin-?3(2H)-?yl)-?2-?-(pyridin-2- yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride
M.Wt
540.54
Purity
>95% by HPLC
Appearance
Liquid
Formulation
DMSO ( 3 mM)
Storage
-20 centigrade
Shipping Conditions
Gel pack
Handling
Protect from light and moisture
Usage
For Research Use Only! Not For Use in Humans.
